News Sentiment

CTOR sentiment intelligence

Citius Oncology, Inc. news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 55 Balanced news tone 50 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Drug Manufacturers - Specialty & Generic Read-through group
Latest close 0.69 Week of 10 Jul 2026
Weighted tone 55/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

82/100 classification confidence.

Company focus 50

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend inactive

+1.6% over one week, +4.1% over four weeks, trend inactive, and below fair value.

Latest direct headline Neutral

CTXR News | CITIUS PHARMACEUTICALS INC (NASDAQ:CTXR)

Market Reaction

Balanced read

65/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 82/100 classification
One-week reaction 1.6% Price digesting
Trend fit Trend inactive 4.1% over four weeks
Fair value -86.1% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 17
Neutral 28
Negative 5

Relevance

Why the article matched

Direct first
Direct company coverage 50
Industry context 0
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 14
PR Newswire 12
TradingView 11
TradingKey 4
ChartMill 1
Investing.com 1
Investing.com Nigeria 1
Finviz 1

Event Lens

What the news is about

Classified themes
Market update 31
Earnings 13
Analyst action 2
Balance sheet 2
Capital return 1
Deals and strategy 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 50
TradingView Direct company coverage

Enterprise value to EBITDA forward of Citius Oncology, Inc. – NASDAQ:CTOR

This page displays the enterprise value to EBITDA forward for Citius Oncology, Inc. (NASDAQ: CTOR). It is primarily a financial data point from TradingView, indicating no current trades and providing a basic overview of the company's financial metrics. The article provides no spe

Tone
Neutral 50/100
Event
Market update
Published
27 Jun 2026 02:11
Source
TradingView
TradingView Direct company coverage

Citius Oncology, Inc. Actuals & Estimates (NASDAQ:CTOR)

This article provides an overview of Citius Oncology, Inc. (NASDAQ:CTOR) stock performance, analyst estimates, and financial data. It highlights the current stock price, recent declines, future price forecasts from analysts, historical highs and lows, and upcoming earnings report

Tone
Negative 34/100
Event
Earnings
Published
26 Jun 2026 21:09
Source
TradingView
TradingView Direct company coverage

Price to sales forward of Citius Oncology, Inc. – NASDAQ:CTOR

This article provides a financial overview of Citius Oncology, Inc. (NASDAQ: CTOR), specifically focusing on its forward price-to-sales ratio. It appears to be a stub or preview from a financial data platform like TradingView, indicating that the detailed financial data for this

Tone
Neutral 50/100
Event
Market update
Published
26 Jun 2026 17:10
Source
TradingView
TradingView Direct company coverage

Citius Oncology, Inc. Actuals & Estimates (BOATS:CTOR)

This article provides an overview of Citius Oncology, Inc. (CTOR) stock performance and financial estimates. It details analyst forecasts, historical price data, upcoming earnings reports, and past financial results including earnings per share, revenue, and net income, noting th

Tone
Negative 38/100
Event
Earnings
Published
26 Jun 2026 12:11
Source
TradingView
TradingView Direct company coverage

CTOR Forecast — Price Target — Prediction for 2027

This article provides a forecast for Citius Oncology, Inc. (CTOR) stock, including a 1-year price target of $4.00 from one analyst. It details current stock performance, market capitalization, volatility, and historical price data. The piece also covers financial information like

Tone
Negative 38/100
Event
Analyst action
Published
26 Jun 2026 07:10
Source
TradingView
TradingKey Direct company coverage

Citius Oncology Inc (CTOR) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Citius Oncology Inc (CTOR), noting its current valuation score of 7.36 within the Biotechnology & Medical Research industry. It highlights the company's current P/E ratio of -1.43, which is positioned between its recent high and low,

Tone
Neutral 50/100
Event
Market update
Published
24 Jun 2026 09:11
Source
TradingKey
TradingKey Direct company coverage

Citius Oncology Inc (CTOR) Earnings Forecast: Future EPS & Revenue Growth Estimates

Citius Oncology Inc (CTOR) has an earnings forecast score of 8.00, placing it well within the Biotechnology & Medical Research industry. Analysts have set an average price target of $6.00 for the stock, with a consensus of "Buy" based on one analyst's rating. The company's expect

Tone
Positive 71/100
Event
Earnings
Published
18 Jun 2026 04:40
Source
TradingKey
TradingKey Direct company coverage

Citius Oncology Inc (CTOR) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Citius Oncology Inc's (CTOR) dividend and stock split history. It indicates that the company has not distributed any dividends over the past five years and has no recorded stock split data. The page also displays current stock price informatio

Tone
Neutral 50/100
Event
Capital return
Published
18 Jun 2026 01:40
Source
TradingKey
TradingKey Direct company coverage

Citius Oncology Inc (CTOR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article from TradingKey attempts to provide a revenue breakdown for Citius Oncology Inc (CTOR), including business segments, regional revenue, and profit contribution. However, the article explicitly states that relevant data have not been disclosed by the company yet, makin

Tone
Neutral 50/100
Event
Earnings
Published
18 Jun 2026 00:40
Source
TradingKey
TradingView Direct company coverage

Citius Oncology, Inc. Financial Disclosures & SEC Filings

This page provides access to Citius Oncology, Inc.'s financial disclosures and SEC filings, including Forms 10-K, 10-Q, and 8-K. It details key corporate events, earnings reports, and operational updates from 2024 to early 2026, highlighting the launch and impact of their product

Tone
Positive 62/100
Event
Earnings
Published
04 Jun 2026 11:10
Source
TradingView
Stock Titan Direct company coverage

Citius Oncology (CTOR) registers 6.8M warrant shares; highlights Phase 1 LYMPHIR data

Citius Oncology (CTOR) has registered 6.8 million warrant shares, leading to approximately $6.1 million in net proceeds for the company. Concurrently, the company highlighted positive Phase 1 clinical data for LYMPHIR in combination with pembrolizumab, showing durable responses a

Tone
Positive 61/100
Event
Market update
Published
03 Jun 2026 01:10
Source
Stock Titan
Stock Titan Direct company coverage

Citius Oncology (NASDAQ: CTOR) highlights Phase 1 LYMPHIR plus pembrolizumab results

Citius Oncology (NASDAQ: CTOR) announced encouraging early Phase 1 data for its drug LYMPHIR in combination with pembrolizumab in heavily pre-treated patients with recurrent or refractory gynecologic cancers. The study showed a 48% clinical benefit rate among efficacy-evaluable p

Tone
Positive 64/100
Event
Earnings
Published
02 Jun 2026 00:39
Source
Stock Titan
Investing.com Direct company coverage

Citius Oncology presents study data on LYMPHIR combination

Citius Oncology presented Phase 1 clinical data for LYMPHIR in combination with pembrolizumab for recurrent or refractory gynecologic malignancies at the American Society of Clinical Oncology Annual Meeting. The study showed a 24% overall response rate with five partial responses

Tone
Neutral 50/100
Event
Market update
Published
01 Jun 2026 22:11
Source
Investing.com
Investing.com Nigeria Direct company coverage

Citius Oncology presents study data on LYMPHIR combination By Investing.com

Citius Oncology presented positive Phase 1 clinical data for LYMPHIR in combination with pembrolizumab for recurrent or refractory gynecologic malignancies at the American Society of Clinical Oncology Annual Meeting. The study showed a 24% overall response rate and a 33% objectiv

Tone
Positive 65/100
Event
Market update
Published
01 Jun 2026 11:40
Source
Investing.com Nigeria
PR Newswire Direct company coverage

Citius Oncology Highlights Phase 1 Data in an Investigator-Initiated Study of LYMPHIR® (denileukin diftitox-cxdl) in Combination with Pembrolizumab in Recurrent or Refractory Gynecologic Malignancies

Citius Oncology announced encouraging Phase 1 clinical data for LYMPHIR (denileukin diftitox-cxdl) in combination with pembrolizumab for recurrent or refractory gynecologic malignancies, presented at the ASCO Annual Meeting. The study demonstrated durable responses and manageable

Tone
Positive 74/100
Event
Market update
Published
01 Jun 2026 07:00
Source
PR Newswire
Finviz Direct company coverage

CTOR - Citius Oncology Inc Stock Price and Quote

This article provides detailed stock information for Citius Oncology Inc. (CTOR), including its current stock price, financial metrics, analyst ratings, and recent news announcements. Key highlights include the company's financial performance, insider and institutional ownership,

Tone
Positive 66/100
Event
Analyst action
Published
29 May 2026 21:41
Source
Finviz
Stock Titan Direct company coverage

Citius Oncology (NASDAQ: CTOR) clears potential $25M loan conversions and large warrants

Citius Oncology (NASDAQ: CTOR) has informed stockholders that a majority holder approved, via written consent, the potential issuance of common stock related to a Loan and Security Agreement and several warrant transactions. These actions, which include a $25.0 million loan facil

Tone
Neutral 50/100
Event
Market update
Published
29 May 2026 21:10
Source
Stock Titan
Stock Titan Direct company coverage

Citius Oncology (Nasdaq: CTOR) registers 32.9M shares tied to warrants and loan conversion

Citius Oncology (Nasdaq: CTOR) has registered 32.9 million shares of common stock for resale by selling stockholders, stemming from warrant exercises and loan conversions. The company will not receive proceeds from these resales, but could gain up to $26.5 million if all warrants

Tone
Negative 38/100
Event
Market update
Published
29 May 2026 20:10
Source
Stock Titan
TradingView Direct company coverage

Number of shareholders of Citius Oncology, Inc. – NASDAQ:CTOR

This article provides details on the number of shareholders for Citius Oncology, Inc. (NASDAQ: CTOR). It indicates that the data is presented for a specific period, showing its value and percentage change. The content also includes various disclaimers regarding data sources.

Tone
Neutral 50/100
Event
Market update
Published
26 May 2026 17:10
Source
TradingView
Stock Titan Direct company coverage

Citius Oncology (CTOR) registers 6.82M warrant shares; May 2026 financing steps

Citius Oncology (CTOR) registered 6.82 million shares underlying warrants and confirmed 272,727 placement agent warrants remain outstanding as of a May 15, 2026 prospectus supplement. The company received approximately $6.1 million in net proceeds from warrant exercises at a redu

Tone
Neutral 50/100
Event
Market update
Published
22 May 2026 20:39
Source
Stock Titan
Stock Titan Direct company coverage

Citius Oncology (NASDAQ: CTOR) majority approves warrant and conversion issuances

Citius Oncology (NASDAQ: CTOR) announced that a majority of its shareholders approved the issuance of common stock related to lender warrants, May 2026 warrants, amended December 2025 warrants, and a lender conversion option. These approvals are linked to a $25.0 million loan pac

Tone
Neutral 50/100
Event
Market update
Published
19 May 2026 20:09
Source
Stock Titan
Stock Titan Direct company coverage

LYMPHIR cancer drug at 83% of target accounts, coverage near 100%

Citius Oncology reported Q2 2026 financial results, including $1.7 million in quarterly LYMPHIR revenue and $5.6 million for the first half of fiscal 2026, with an 80% gross margin. The company achieved broad market access for LYMPHIR, with 83% of target accounts having it on for

Tone
Negative 39/100
Event
Earnings
Published
19 May 2026 19:09
Source
Stock Titan
Stock Titan Direct company coverage

Armistice Capital (CTOR) files 9.99% ownership disclosure

Armistice Capital, LLC and Steven Boyd have reported a beneficial ownership of 9,299,917 shares, representing 9.99% of Citius Oncology, Inc. (CTOR) common stock as of March 31, 2026. This ownership is held through Armistice Capital Master Fund Ltd., with Armistice Capital and Mr.

Tone
Neutral 50/100
Event
Market update
Published
16 May 2026 03:09
Source
Stock Titan
TradingView Direct company coverage

CITIUS ONCOLOGY, INC. 3Q 2026: Revenue $1.67M, EPS $(0.27) — 10-Q Summary

CITIUS ONCOLOGY, INC. (CTOR) reported first commercial revenue of $1.67 million for the third quarter ended March 31, 2026, marking a significant milestone from zero revenue in the prior year. Despite this, the company posted a net loss of $(26.61M) or diluted loss per share of $

Tone
Positive 63/100
Event
Earnings
Published
15 May 2026 20:39
Source
TradingView
TradingView Direct company coverage

Citius Oncology reports $5.6M H1 revenue, $26.6M Q2 net loss; secures up to $36.5M financing

Citius Oncology reported $5.6 million in product revenue for the first half of FY2026, driven by the December 2025 launch of LYMPHIR, and a Q2 net loss of $26.6 million. The company secured up to $36.5 million in post-quarter-end debt and equity financing to support commercial op

Tone
Positive 61/100
Event
Earnings
Published
15 May 2026 20:39
Source
TradingView